|
| Status |
Public on Aug 13, 2010 |
| Title |
Endocrine Sensitivity Index Validation Dataset |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Validation dataset of 298 ER-positive patients treated with tamoxifen for 5 years.
All patients in this dataset have ER+ breast cancer and were uniformly treated with tamoxifen for 5 years. The objective of the study was to correlate levels of genomic markers to outcomes (relapse free survival) in this cohort of uniformly treated patients.
|
| |
|
| Overall design |
Tissue samples were processed and profiled by two different labs (MD Anderson Cancer Center and Jules Bordet Institute).
|
| |
|
| Contributor(s) |
Symmans WF, Sotiriou C, Andre F, Regitnig P, Daxenbichler G, Hatzis C |
| Citation(s) |
20697068 |
| |
| Submission date |
Aug 18, 2009 |
| Last update date |
Aug 10, 2018 |
| Contact name |
Christos Hatzis |
| E-mail(s) |
christos@nuverabio.com
|
| Phone |
781-938-3830
|
| URL |
http://www.nuverabio.com
|
| Organization name |
Nuvera Biosciences
|
| Street address |
400 West Cummings Park, Suite 5350
|
| City |
Woburn |
| State/province |
MA |
| ZIP/Postal code |
01801 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL96 |
[HG-U133A] Affymetrix Human Genome U133A Array |
|
| Samples (298)
|
|
| Relations |
| BioProject |
PRJNA118415 |
Less...
More...